Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the combination of ONCOS-102 and pembrolizumab (Keytruda) has demonstrated 35% best objective response rate (ORR) in anti-PD1 refractory malignant melanoma.
Archive | Clinical Trials
Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
Posted in Melanoma News, Health Professionals, Clinical Trials
Immune-Boosting Components Double the Effectiveness of Melanoma Vaccine Candidate in Phase II Trial
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system dendritic cells (DCs), according to the results of a Phase II clinical trial published in Nature Cancer.
Posted in Melanoma News, Health Professionals, Clinical Trials
Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 trial
In this phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial, researchers sought to assess pembrolizumab vs placebo in patients with resected high-risk stage III melanoma.
Posted in Melanoma News, Health Professionals, Clinical Trials
Phase 3 Study Shows Statistically Significant Survival With Tebentafusp in Metastatic Uveal Melanoma
Overall survival (OS) was statistically significantly improved with tebentafusp compared with investigator’s choice of therapy as treatment of patients with metastatic uveal melanoma in the phase 3 IMCgp100-202 study (NCT03070392), Immunocore announced in a press release.
Posted in Melanoma News, Health Professionals, Clinical Trials
